In CRC, the US Food and Drug Administration approved nivolumab as a treatment modality in MMR-deficient/MSI-H metastatic CRC refractory to fluoropyrimidine, oxaliplatin, and irinotecan69, although PD-L1 has not yet been approved as an immunotherapy predictive marker. Here, MRC1 is linked to colorectal carcinoma.